Current Neurology and Neuroscience Reports

, Volume 10, Issue 4, pp 252–258

Primary Brain Tumors in the Elderly



The incidence of primary brain tumors is highest in elderly patients, and advanced age often is a negative prognostic factor. Nevertheless, large randomized studies in this population are scarce. Elderly patients with primary brain tumors also present unique challenges, such as the presence of multiple comorbidities and polypharmacy, decreased tolerance to chemotherapy, and an increased risk for radiation-induced neurotoxicity. This review gives an overview of the treatment options for older patients with glioblastoma and other gliomas, primary central nervous system lymphomas (PCNSLs), and meningiomas. Selected elderly glioblastoma patients with good performance status may benefit from aggressive treatment with surgical resection, radiotherapy, and possibly chemotherapy. For older patients with PCNSLs, high-dose methotrexate-based chemotherapy should be the mainstay option; whole-brain radiation therapy should be avoided in chemosensitive tumors because of the high risk of irreversible and progressive neurotoxicity. Meningiomas often may be followed up in elderly patients, as they usually are asymptomatic and have a slow growth rate. Treatment for elderly patients with primary brain tumors should be individualized, and age alone should not preclude the use of more aggressive treatments.


Elderly Glioma Glioblastoma Oligodendroglioma Astrocytoma Primary central nervous system lymphoma Meningioma Primary brain tumor Chemotherapy Radiotherapy 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Central Brain Tumor Registry of the United States: 2009 CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004–2005. Available at Accessed February 1, 2010.
  2. 2.
    Wrensch M, Minn Y, Chew T, et al.: Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol 2002, 4:278–299.CrossRefPubMedGoogle Scholar
  3. 3.
    • Iwamoto FM, Reiner AS, Panageas KS, et al.: Patterns of care in elderly glioblastoma patients. Ann Neurol 2008, 64:628–634. This large population-based study describes the patterns of care for elderly glioblastoma patients in the United States.CrossRefPubMedGoogle Scholar
  4. 4.
    Brandes AA, Compostella A, Blatt V, Tosoni A: Glioblastoma in the elderly: current and future trends. Crit Rev Oncol Hematol 2006, 60:256–266.CrossRefPubMedGoogle Scholar
  5. 5.
    Batchelor TT, Betensky RA, Esposito JM, et al.: Age-dependent prognostic effects of genetic alterations in glioblastoma. Clin Cancer Res 2004, 10:228–233.CrossRefPubMedGoogle Scholar
  6. 6.
    Simmons ML, Lamborn KR, Takahashi M, et al.: Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 2001, 61:1122–1128.PubMedGoogle Scholar
  7. 7.
    Kleinschmidt-DeMasters BK, Lillehei KO, Varella-Garcia M: Glioblastomas in the older old. Arch Pathol Lab Med 2005, 129:624–631.PubMedGoogle Scholar
  8. 8.
    Iwamoto FM, Cooper AR, Reiner AS, et al.: Glioblastoma in the elderly: the Memorial Sloan-Kettering Cancer Center experience (1997–2007). Cancer 2009, 115:3758–3766.CrossRefPubMedGoogle Scholar
  9. 9.
    Stupp R, Mason WP, van den Bent MJ, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987–996.CrossRefPubMedGoogle Scholar
  10. 10.
    McGirt MJ, Chaichana KL, Gathinji M, et al.: Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J Neurosurg 2009, 110:156–162.CrossRefPubMedGoogle Scholar
  11. 11.
    Kita D, Ciernik IF, Vaccarella S, et al.: Age as a predictive factor in glioblastomas: population-based study. Neuroepidemiology 2009, 33:17–22.CrossRefPubMedGoogle Scholar
  12. 12.
    Vuorinen V, Hinkka S, Farkkila M, Jaaskelainen J: Debulking or biopsy of malignant glioma in elderly people—a randomised study. Acta Neurochir (Wien) 2003, 145:5–10.CrossRefGoogle Scholar
  13. 13.
    Walker MD, Alexander E Jr, Hunt WE, et al.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 1978, 49:333–343.CrossRefPubMedGoogle Scholar
  14. 14.
    Paszat L, Laperriere N, Groome P, et al.: A population-based study of glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001, 51:100–107.PubMedGoogle Scholar
  15. 15.
    •• Keime-Guibert F, Chinot O, Taillandier L, et al.: Radiotherapy for glioblastoma in the elderly. N Engl J Med 2007, 356:1527–1535. This randomized study showed a survival benefit for radiotherapy compared with supportive care only for glioblastoma patients older than 70 years.CrossRefPubMedGoogle Scholar
  16. 16.
    Walker MD, Strike TA, Sheline GE: An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979, 5:1725–1731.PubMedGoogle Scholar
  17. 17.
    Roa W, Brasher PM, Bauman G, et al.: Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol 2004, 22:1583–1588.CrossRefPubMedGoogle Scholar
  18. 18.
    Bauman GS, Gaspar LE, Fisher BJ, et al.: A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 1994, 29:835–839.PubMedGoogle Scholar
  19. 19.
    Minniti G, De Sanctis V, Muni R, et al.: Hypofractionated radiotherapy followed by adjuvant chemotherapy with temozolomide in elderly patients with glioblastoma. J Neurooncol 2009, 91:95–100.CrossRefPubMedGoogle Scholar
  20. 20.
    Fine HA, Dear KB, Loeffler JS, et al.: Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993, 71:2585–2597.CrossRefPubMedGoogle Scholar
  21. 21.
    Stewart LA: Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002, 359:1011–1018.CrossRefPubMedGoogle Scholar
  22. 22.
    Brandes AA, Vastola F, Basso U, et al.: A prospective study on glioblastoma in the elderly. Cancer 2003, 97:657–662.CrossRefPubMedGoogle Scholar
  23. 23.
    Minniti G, De Sanctis V, Muni R, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma in elderly patients. J Neurooncol 2008, 88:97–103.CrossRefPubMedGoogle Scholar
  24. 24.
    Combs SE, Wagner J, Bischof M, et al.: Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 2008, 70:987–992.PubMedGoogle Scholar
  25. 25.
    Sijben AE, McIntyre JB, Roldan GB, et al.: Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol 2008, 89:97–103.CrossRefPubMedGoogle Scholar
  26. 26.
    Chinot OL, Barrie M, Frauger E, et al.: Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer 2004, 100:2208–2214.CrossRefPubMedGoogle Scholar
  27. 27.
    Glantz M, Chamberlain M, Liu Q, et al.: Temozolomide as an alternative to irradiation for elderly patients with newly diagnosed malignant gliomas. Cancer 2003, 97:2262–2266.CrossRefPubMedGoogle Scholar
  28. 28.
    Friedman HS, Prados MD, Wen PY, et al.: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009, 27:4733–4740.CrossRefPubMedGoogle Scholar
  29. 29.
    Kreisl TN, Kim L, Moore K, et al.: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009, 27:740–745.CrossRefPubMedGoogle Scholar
  30. 30.
    Wu W, Lamborn KR, Buckner JC, et al.: Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma. Neuro Oncol 2010, 12:164–172.PubMedGoogle Scholar
  31. 31.
    Nghiemphu PL, Liu W, Lee Y, et al.: Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009, 72:1217–1222.CrossRefPubMedGoogle Scholar
  32. 32.
    Iwamoto FM, Reiner AS, Nayak L, et al.: Prognosis and patterns of care in elderly patients with glioma. Cancer 2009, 115:5534–5540.CrossRefPubMedGoogle Scholar
  33. 33.
    Kaloshi G, Psimaras D, Mokhtari K, et al.: Supratentorial low-grade gliomas in older patients. Neurology 2009, 73:2093–2098.CrossRefPubMedGoogle Scholar
  34. 34.
    van den Bent MJ, Afra D, de Witte O, et al.: Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005, 366:985–990.CrossRefPubMedGoogle Scholar
  35. 35.
    Olson JE, Janney CA, Rao RD, et al.: The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a surveillance, epidemiology, and end results analysis. Cancer 2002, 95:1504–1510.CrossRefPubMedGoogle Scholar
  36. 36.
    • Abrey LE, Ben-Porat L, Panageas KS, et al.: Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006, 24:5711–5715. In this large study of PCNSL, older age was one of the most important negative prognostic factors.CrossRefPubMedGoogle Scholar
  37. 37.
    Nelson DF, Martz KL, Bonner H, et al.: Non-Hodgkin’s lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group (RTOG): RTOG 8315. Int J Radiat Oncol Biol Phys 1992, 23:9–17.PubMedGoogle Scholar
  38. 38.
    DeAngelis LM, Seiferheld W, Schold SC, et al.: Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002, 20:4643–4648.CrossRefPubMedGoogle Scholar
  39. 39.
    Abrey LE, Yahalom J, DeAngelis LM: Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000, 18:3144–3150.PubMedGoogle Scholar
  40. 40.
    Hoang-Xuan K, Taillandier L, Chinot O, et al.: Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003, 21:2726–2731.CrossRefPubMedGoogle Scholar
  41. 41.
    Zhu JJ, Gerstner ER, Engler DA, et al.: High-dose methotrexate for elderly patients with primary CNS lymphoma. Neuro Oncol 2009, 11:211–215.CrossRefPubMedGoogle Scholar
  42. 42.
    Omuro AM, Taillandier L, Chinot O, et al.: Temozolomide and methotrexate for primary central nervous system lymphoma in the elderly. J Neurooncol 2007, 85:207–211.CrossRefPubMedGoogle Scholar
  43. 43.
    Ney DE, Reiner AS, Skinner HD, et al.: Characteristics and outcomes of elderly patients with primary CNS lymphoma (PCNSL). J Clin Oncol (Meeting Abstracts) 2009, 27:2070.Google Scholar
  44. 44.
    Panageas KS, Elkin EB, Ben-Porat L, et al.: Patterns of treatment in older adults with primary central nervous system lymphoma. Cancer 2007, 110:1338–1344.CrossRefPubMedGoogle Scholar
  45. 45.
    Nakamura M, Roser F, Michel J, et al.: The natural history of incidental meningiomas. Neurosurgery 2003, 53:62–70; discussion 70–61.CrossRefPubMedGoogle Scholar
  46. 46.
    Bateman BT, Pile-Spellman J, Gutin PH, Berman MF: Meningioma resection in the elderly: nationwide inpatient sample, 1998–2002. Neurosurgery 2005, 57:866–872; discussion 866–872.CrossRefPubMedGoogle Scholar
  47. 47.
    Niiro M, Yatsushiro K, Nakamura K, et al.: Natural history of elderly patients with asymptomatic meningiomas. J Neurol Neurosurg Psychiatry 2000, 68:25–28.CrossRefPubMedGoogle Scholar
  48. 48.
    Braunstein JB, Vick NA: Meningiomas: the decision not to operate. Neurology 1997, 48:1459–1462.PubMedGoogle Scholar
  49. 49.
    Coke CC, Corn BW, Werner-Wasik M, et al.: Atypical and malignant meningiomas: an outcome report of seventeen cases. J Neurooncol 1998, 39:65–70.CrossRefPubMedGoogle Scholar

Copyright information

© US Government 2010

Authors and Affiliations

  1. 1.Department of NeurologyMemorial Sloan-Kettering Cancer CenterNew YorkUSA
  2. 2.Neuro-Oncology BranchNational Cancer Institute, National Institute of Neurological Disorders and Stroke, National Institutes of HealthBethesdaUSA

Personalised recommendations